Threshold Pharmaceuticals to reduce workforce
Threshold to focus on clinical trials of tarloxotinib while evaluating potential further development of evofosfamide and other strategic options for the company.
Threshold Pharmaceuticals has initiated a significant reduction in its workforce in order to focus the company's financial resources in the near term on two ongoing Phase II proof-of-concept clinical trials of tarloxotinib bromide ("tarloxotinib"), the company's novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) licensed from the University of Auckland, New Zealand.
Threshold will reduce its workforce by approximately two-thirds, resulting in between 20-25 remaining employees. Threshold anticipates the one-time severance-related charge associated with the workforce reduction to be approximately $2.6 million, which includes approximately $0.3 million of non-cash expense related to the extension of the post-termination exercise period for the outstanding vested stock options for the affected employees. The majority of the charges will be paid by the end of the first quarter of 2016.
"We are enacting this reduction in workforce as a result of the recently announced outcomes from our two Phase III trials of evofosfamide in which neither trial met its primary endpoint of demonstrating a statistically significant improvement in overall survival," said Barry Selick, CEO at Threshold. "I would like to express my sincere gratitude to our employees who are being affected by this difficult but necessary action. This is a loss to our Threshold family of talented and dedicated individuals who have worked with integrity and passion towards improving the lives of people living with cancer."
Dr Selick continued, "With this workforce reduction, we will focus our efforts on the ongoing Phase II clinical trials of tarloxotinib while evaluating potential further development of evofosfamide and other strategic options for the company. We plan to provide additional guidance in the first quarter of 2016."
Threshold has a global license and co-development agreement for evofosfamide with Merck KGaA, Darmstadt, Germany. Both companies are evaluating next steps for the evofosfamide program.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance